Navigation Links
Halozyme to Host First Quarter 2012 Financial Results Conference Call
Date:4/30/2012

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection)
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
2. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
3. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
4. Halozyme Announces Proposed Public Offering of Common Stock
5. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
6. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
7. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
8. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
9. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
10. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
11. Halozyme Therapeutics to Present at Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... announces the appointment of Jarrod Longcor ... Longcor is responsible for structuring, negotiating and executing ... as well as providing management and strategic leadership ... the Executive leadership team. Mr Longcor ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... 22, 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: ... to sell $200 million of its common stock in ... and BofA Merrill Lynch are acting as joint book-running ... a 30-day option to purchase additional shares of its ... in the offering are being sold by Avanir.  The ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... The Dutch biotech company Skyline Diagnostics B.V. (Skyline) ... (Clavis) disclosed signing a research agreement. Under this agreement, ... individual Acute Myeloid Leukemia (AML) patients that may benefit ... This drug, elacytarabine, is a novel elaidic acid derivative ...
... demonstrate its continued commitment to innovative immunoglobulin (Ig) research, ... is seeking proposals for the next round of Interlaken ... program provides monetary grants and/or product supply to advance medical ... in the treatment of neurological disorders. From the ...
Cached Medicine Technology:Skyline Diagnostics and Clavis Pharma to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug elacytarabine 2CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology 2CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology 3
(Date:9/23/2014)... has awarded $10.1 million in supplemental funding to bolster ... of sex in preclinical and clinical studies. , This ... is a catalyst for considering sex as a fundamental ... in preclinical research can obscure key findings related to ... approach will result in greater awareness of the need ...
(Date:9/23/2014)... The Westlake Village sedation dentist ... oral sedation with treatment for new patients. Studies have ... dental anxiety or dental phobia. These common conditions are ... keep patients from seeking desperately needed dental care. , ... and surrounding areas now have an opportunity to manage ...
(Date:9/23/2014)... September 23, 2014 Kenall Manufacturing, ... expanded its MedMaster™ M4 product line with a ... the M4 product line – currently available with ... – providing more flexibility when designing lighting for ... MedMaster M4 Series include:, •Three sizes available ...
(Date:9/23/2014)... 23, 2014 Catalent Pharma ... delivery technologies and development solutions for drugs, ... that it had reached an exclusive development ... company, Cingulate Therapeutics (CTx), to support the ... pharmaceutical products for the treatment of Attention ...
(Date:9/23/2014)... losing your job can increase the risk for developing asthma, ... more than 7,000 employed adults in Germany. Between 2009 and ... questions about the respiratory disorder and also on whether they ... More than 100 new cases of asthma were diagnosed among ... study period. The researchers noted that for every 25 ...
Breaking Medicine News(10 mins):Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 2Health News:Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2
... Alberta - A University of Alberta researcher in collaboration ... really does come with age, at least when it ... Dr. Florin Dolcos, assistant professor of psychiatry and neuroscience ... patterns that help healthy older people regulate and control ...
... 12 Not so long ago, any mention ... images of third-world,children with rickets and bone deformities. ... world to the developed, where Vitamin D deficiency,among ... rising to,astronomical proportions -- by some estimates, affecting ...
... Would Have Improved Benefits for Prevention, Mental,Health ... HARRISBURG, Pa., June 12 SUMMARY: ... critical legislation to protect and,improve Medicare for ... it. The,Medicare Improvements for Patients and Providers ...
... Serve Elective Cash Pay ... Patients, ... services for elective (cash pay) surgery, today,announced a leap forward in its ... bariatric surgeons, cash pay business.,Beginning July 1st, 2008, the BLISCare(SM) insurance policy ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
... MEDRAD, INC., has signed a,distribution and ... owned subsidiary of Siemens Medical Solutions USA, ... to inject Fluorodeoxyglucose,(FDG) for Positron Emission Tomography/Computed ... way. The partnership will leverage,MEDRAD,s soon to ...
Cached Medicine News:Health News:New research shows how aging brain brings a healthy dose of perspective 2Health News:Spotting Vitamin-D Deficiency in the Absence of Symptoms: ZRT Laboratory's New, One-of-a-Kind Blood Spot Test Answers the Call for Early Detection of Rapidly Rising D-Deficiencies 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP PENNSYLVANIA NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 2Health News:BLIS to Offer Coverage Through 'A' Rated Insurance Carrier 3Health News:Better Sleepers Are 'Successful Agers' 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 2Health News:MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery 3
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Medicine Products: